Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s share price shot up 6.3% on Monday after BMO Capital Markets raised their price target on the stock from $177.00 to $180.00. BMO Capital Markets currently has an outperform rating on the stock. Alexion Pharmaceuticals traded as high as $115.98 and last traded at $115.43. 2,651,232 shares changed hands during trading, an increase of 26% from the average session volume of 2,110,139 shares. The stock had previously closed at $108.60.

ALXN has been the topic of several other reports. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Leerink Swann decreased their price target on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a report on Friday. Raymond James Financial reissued an “outperform” rating and set a $130.00 price target (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada raised their price target on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $152.77.

In related news, CEO Ludwig Hantson sold 13,245 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $1,540,525.95. Following the completion of the transaction, the chief executive officer now owns 131,425 shares in the company, valued at $15,286,041.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP John B. Moriarty sold 3,363 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $115.70, for a total value of $389,099.10. Following the completion of the transaction, the executive vice president now owns 71,400 shares of the company’s stock, valued at approximately $8,260,980. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,930 shares of company stock valued at $3,378,199. 4.35% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vatera Holdings LLC purchased a new position in Alexion Pharmaceuticals in the fourth quarter worth about $2,954,000. Eversept Partners LLC purchased a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at approximately $4,006,000. Sphera Funds Management LTD. purchased a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at approximately $14,351,000. Johnson Financial Group Inc. boosted its position in shares of Alexion Pharmaceuticals by 22.4% during the fourth quarter. Johnson Financial Group Inc. now owns 5,120 shares of the biopharmaceutical company’s stock valued at $612,000 after buying an additional 938 shares during the period. Finally, Eaton Vance Management boosted its position in shares of Alexion Pharmaceuticals by 18.2% during the fourth quarter. Eaton Vance Management now owns 1,098,596 shares of the biopharmaceutical company’s stock valued at $131,381,000 after buying an additional 169,542 shares during the period. Institutional investors own 94.01% of the company’s stock.

The company has a market cap of $25,790.00, a PE ratio of 58.59, a PEG ratio of 0.95 and a beta of 1.16. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same quarter in the previous year, the business earned $1.26 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 6.25 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Shares Up 6.3% on Analyst Upgrade” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://theolympiareport.com/2018/02/12/alexion-pharmaceuticals-alxn-shares-up-6-3-on-analyst-upgrade.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.